ARY News Live3h
VYLOY: Astellas’ gastric cancer therapy approved in US
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...
Knowridge10h
Research finds the cause of rising colorectal cancer cases in young people
Colorectal cancer, which affects the colon or rectum, is on the rise among people under 50, sparking alarm among doctors and ...
Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
Channel NewsAsia Singapore18h
In Pictures: Handle with care – dying patients’ pains and their relationships with loved ones
The familiar melody of a Teochew opera caught the attention of 95-year-old Chua Swee Eng.  She glanced over at Ms Katherine ...
devdiscourse22h
Health Update: FDA Approvals, CEO Changes, and Vaccine Progress
FDA's approval of Astellas' therapy for gastric cancer, and CVS Health's leadership shuffle as Karen Lynch steps down amid ...
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...
Managed Healthcare Executive22h
FDA Approves First-in-Class Drug for Gastric Cancer
Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and ...
Astellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ Cancer
Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...
Medscape23h
FDA OKs Zolbetuximab for Gastric, Gastroesophageal Cancer
FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...